Evidence map›Paper›PMID 42601939›Full record

ArticleFrontiers in cellular neuroscience2026

Neurogenesis defects in iPSC-derived midbrain organoids of early-onset Parkinson's disease with 22q11.2 deletion syndrome.

Syugo Ueki, Toshiya Kimura, Rie Tohge, Atsushi Tamada, Mitsuaki Oki, Yusuke Yakushiji, Haruhisa Inoue, Satoshi Kaneko, Keiko Muguruma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Syugo UekiDepartment of Neurology, Kansai Medical University, Hirakata, Japan.
Toshiya KimuraDepartment of iPS Cell Applied Medicine, Graduate School of Medicine, Kansai Medical University, Hirakata, Osaka, Japan.
Rie TohgeDepartment of Neurology, Kansai Medical University, Hirakata, Japan.
Atsushi TamadaDepartment of iPS Cell Applied Medicine, Graduate School of Medicine, Kansai Medical University, Hirakata, Osaka, Japan.
Mitsuaki OkiDepartment of Neurology, Kansai Medical University, Hirakata, Japan.
Yusuke YakushijiDepartment of Neurology, Kansai Medical University, Hirakata, Japan.
Haruhisa InoueiPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC), Kyoto, Japan.
Satoshi KanekoDepartment of Neurology, Kansai Medical University, Hirakata, Japan.
Keiko MugurumaDepartment of iPS Cell Applied Medicine, Graduate School of Medicine, Kansai Medical University, Hirakata, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sporadic Parkinson's disease (PD) is typically a late-onset disorder caused by a combination of genetics, environment, and aging, manifesting when the loss of midbrain dopaminergic neurons exceeds a critical threshold, usually after the age of 50. Conversely, early-onset PD, as observed in cases linked to

Indexed as

22q11.2 deletion syndromedopaminergic neuronfloor plateinduced pluripotent stem cellsmidbrain organoidParkinson's disease

Identifiers

PMID42601939
PMCPMC13472798

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.